Study to Assess the Clinical Efficacy and Safety of a Novel Method of Specific Allergen Immunotherapy in Grass Pollen Allergic Subjects by Epicutanous Allergen Administration

ZU-SkinSIT-001 Single Center Phase I/IIa, Placebo Controlled, Randomized, Double Blind Study to Assess the Clinical Efficacy and Safety of a Novel Method of Specific Allergen Immunotherapy in Grass Pollen Allergic Subjects by Epicutanous Allergen Administration

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00457444

Enrollment

Registered

2007-04-06

Start date

2005-12-31

Completion date

2006-11-30

Last updated

2007-04-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rhinoconjunctivitis

Brief summary

Primary Objective Comparison of the inhibition of the allergic response assessed by nasal provocation test after epicutanous pollen allergen administration and placebo epicutaneous administration. Secondary Objectives Comparison of the efficacy of the placebo with that of the epicutanous pollen allergen administration evaluated by visual analog symptom scales (nasal itching, sneezing, rhinorrhea, conjunctival redness, and lacrimation, lung symptoms ), Comparison of the inhibition of the allergic response assessed by skin prick test after epicutanous pollen allergen administration and placebo epicutaneous administration. * Trial with medicinal product

Interventions

DRUGPollen

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* Written informed consent * History of grass pollen allergic rhinitis * Male and female between 18 years to 65 years * Positive skin prick test to grass pollen * Positive nasal provocation test

Exclusion criteria

* Atopic eczema in history or permanent * Perennial allergic rhinitis * Symptoms of infectious disease with rhinitis in between the last 2 weeks * Surgical intervention in between the last 30 days * Pregnancy or nursing * History of HIV or AIDS * Mastocytosis (cutaneous or systemic) * Significant cardiovascular disease * Hypertension (blood pressure \> 160 / 95) * Significant pulmonary, renal and/or hepatic disease * Significant hematological disorder * Moderate or severe asthma * History of malignancy * History of neurological or psychatric disease * Autoimmune disease * Antihistamines with longed half-lives in the last week * Systemic or topical steroids for 5 days * Active infectious disease * Contraindicated medications: - immunosuppressive agents * Betablockers * ACE-inhibitors * Tricyclic antidepressants * Daily use of Beta-agonists or steroid inhalers * Participation in another clinical trial /study in between the last 60 days * Participation in another clinical trial / study at the moment

Design outcomes

Primary

Measure	Time frame
efficacy	—

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026